Ziccum
6.44 SEK 0%1 investor is following this company
Ziccum is a Swedish pharmaceutical company that develops new preparations of biological medicines. With the company's patented LaminarPace technology, dry preparation forms are developed for products that are currently available in liquid form. Most of the business is found around the Nordic region, and in addition to the main business, the company offers various related products. The company's head office is in Lund.
Revenue
3.75M
EBIT %
-574.93 %
P/E
-
Dividend yield-%
-
Target price
-
Recommendation
-
Updated
-
First North Stockholm
ZICC
Daily low / high price
6.26 / 6.54
SEK
Market cap
99M SEK
Turnover
46.86K SEK
Volume
7.3K
Financial calendar
Interim report
2024-04-29
Interim report
2024-07-30
Interim report
2024-10-29
Annual report
2025-01-29
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
William Lithander | 6.8 % | 6.8 % |
Avanza Pension | 6.3 % | 6.3 % |
Premium
This content is for our Premium customers only.
ShowingAll content types
Ziccum inhalable mRNA/LNP project confirms excellent properties obtained by LaminarPace
Ziccum reports significant progress in 3D-modelling project with model completion
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools